The U.S. Food and Drug Administration confirmed on Thursday that a meeting of its independent advisory panel to discuss the composition of this year's flu vaccine has been canceled and the regulator would instead make recommendations later.

Flu vaccine makers may face a last-minute scramble to produce enough doses after an FDA advisory committee meeting was abruptly canceled.

A March meeting of outside advisers to the US Food and Drug Administration to discuss the composition of flu vaccines for this fall’s flu season has been canceled, a member of the advisory committee told CNN.

This week, the Food and Drug Administration — now with vaccine skeptic Robert F. Kennedy Jr. at the helm — unexpectedly and without reason canceled a March meeting of scientists who advise the FDA on vaccine policy. A similar meeting at the Centers for Disease Control was postponed last week.

The Food and Drug Administration Wednesday abruptly and unexpectedly cancelled a planned March 13 vaccine advisory committee meeting that was to have chosen the flu strains in next year's U.S. flu vaccine.

Each year, flu vaccines are tailored to match the most prevalent virus strains expected to circulate. Without an official strain selection from the FDA, vaccine makers may be forced to rely solely on recommendations from the World Health Organization (WHO), which is set to meet this Friday.

WA U.S. Senator Patty Murray and others expressed grave concerns over the FDA's decision to cancel a critical meeting amid the worst flu season in 15 years.

The FDA's decision to cancel the March meeting raises questions about flu vaccine guidance for manufacturers this year

The Food and Drug Administration abruptly canceled a critical meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which gathers annually in March to determine what flu strains will be covered by next year’s vaccine.